A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

INIS

• glucose 100%
• comparative evaluations 100%
• drugs 75%
• screening 50%
• patients 50%
• blood 50%
• plasma 50%
• fasting 50%
• liver 25%
• women 25%
• control 25%
• safety 25%
• netherlands 25%
• clinical trials 25%
• hospitals 25%
• administration 25%
• design 25%
• kidneys 25%
• range 25%
• clearance 25%
• secretion 25%
• universities 25%
• men 25%
• diet 25%
• insulin 25%
• lipids 25%
• maintenance 25%
• hyperglycemia 25%
• titration 25%
• tid 25%

Keyphrases

• Dutch 100%
• Randomized Double-blind 100%
• Type 2 Diabetes Prevention 100%
• Blind Comparison 100%
• Repaglinide 100%
• Glyburide 100%
• Hemoglobin A1c (HbA1c) 30%
• Adverse Events 20%
• Fasting Plasma Glucose 20%
• Glucose-lowering Drugs 20%
• Blood Glucose Reduction 20%
• Netherlands 10%
• Randomized Controlled Trial 10%
• Clinical Trials 10%
• Type 2 Diabetes Mellitus (T2DM) 10%
• Maastricht 10%
• Insulin Secretion 10%
• Hyperglycemia 10%
• Treatment Duration 10%
• Onset of Action 10%
• Rapid Onset 10%
• Hypoglycemia 10%
• University Hospital 10%
• Serum Lipids 10%
• Titration 10%
• Metformin 10%
• Diabetes Duration 10%
• Optimal Dose 10%
• Previously Treated 10%
• Sulfonylurea 10%
• Sustained Improvement 10%
• Daily Treatment 10%
• Endocrinology 10%
• Impaired Kidney Function 10%
• Hepatic Clearance 10%
• Publication Type 10%
• Metabolic Control 10%
• Maintenance Interval 10%
• Patient Eligibility 10%
• Randomized Double-blind Study 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Repaglinide 100%
• Glibenclamide 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Hemoglobin A1c 30%
• Adverse Event 20%
• Randomized Controlled Trial 10%
• Clinical Trial 10%
• Sulfonylurea 10%
• Metformin 10%
• Hypoglycemia 10%
• Hyperglycemia 10%